Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosis

By Amit G. Singal, M. Volk, A. Waljee, Ravi Salgia, P. Higgins, M. Rogers, Jorge Marrero. Alimentary Pharmacology and Therapeutics, 2009

789 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/6e6fbfb1bcb78fc5c04e3566b838df49883e2786

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Hepatology

Citations in the corpus

Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases (2019, background): “(463) These risks justify surveillance strategies that include hepatic ultrasonography, with or without serum alphafetoprotein (AFP) level, every 6 months in patients with cirrhosis(466-468) and adherence to standard guidelines for detection of extrahepatic malignancy.”
Management of hepatocellular carcinoma: An update (2011, neutral): “Analysis of recent studies show that alpha-fetoprotein determination lacks adequate sensitivity and specificity for effective surveillance (and for diagnosis).(5,6) Thus, surveillance has to be based on ultrasound examination.”
A Primer on Effectiveness and Efficacy Trials (2014, result): “However, in a recent effectiveness study, ultrasound only had a sensitivity of 32%, comparable to that of alpha fetoprotein (sensitivity 46%).(9,10) This gap was related to the low utilization rates of ultrasound and its operatordependent nature.”
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “The combination with AFP is not recommended, as the 6–8% gain in the detection rate does not counterbalance the increase in false positive results, ultimately leading to an about 80% increase in the cost of each small HCC diagnosed [69,85].”
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “The combination with AFP is not recommended, as the 6–8% gain in the detection rate does not counterbalance the increase in false positive results, ultimately leading to an about 80% increase in the cost of each small HCC diagnosed [69,85].”
Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis (2014, background): “Subset analyses were planned for type of surveillance tests and surveillance interval, as both have been previously demonstrated to affect surveillance efficacy [16].”
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, background): “A meta-analysis has demonstrated that the pooled sensitivity of a US-based 6-month surveillance strategy drops to 50 from 70% for an annual program [223].”